Clinical Trials Logo

Clinical Trial Summary

This study is a single-center prospective, randomized and quasi double blinded pilot study. The study has 2 parallel arms, each arm involved around 54 patients. Targeted community is the newly diagnosed adults with non metastatic and non inflammatory breast cancer in King Hussein Cancer Center who require axillary biopsy as part of their staging work up. The study aims to improve the intra-operative identification of the preoperatively suspicious and biopsied lymph nodes and test the concordance between the pre-operative clinical suspicion and histopathological results of these node; by comparing between preoperative marking of biopsied axillary lymph nodes with two different modalities (clipping Vs tattooing) and testing its concordance with sentinel lymph node biopsy, both in upfront surgery and neoadjuvant chemotherapy settings and in a prospective, randomized and quasi double blinded design


Clinical Trial Description

This study is a single-center prospective, randomized and quasi double blinded pilot study. The study will enclose 2 parallel arms, each arm will involve 54 patients (total 108 patients), comparing between preoperative marking of biopsied axillary lymph nodes with two different modalities (clipping Vs tattooing) and testing its concordance with sentinel lymph node biopsy, both in upfront surgery and neoadjuvant chemotherapy settings and in a prospective, randomized and quasi double blinded design. Targeted community is the newly diagnosed adults (more than 18 years of age) with non metastatic and non inflammatory breast cancer in King Hussein Cancer Center who require axillary biopsy as part of their staging work up. The standards of breast cancer care in KHCC state that all patients are required to do breast and axillary staging via clinical examination and imaging (mammogram and U/S), and require any patient with clinically suspicious axillary lymph node/nodes to undergo U/S guided axillary biopsy. Patients with negative axillary biopsy will require axillary sentinel lymph node biopsy and patients having positive axillary lymph node biopsy will require axillary clearance along with their standard breast cancer surgical treatment. Once the need for axillary biopsy is defined, the patients offered to participate in the study in a proper environment and their consent was gained after their approval. Participants were given another appointment few days later to obtain the axillary biopsy (as per the routine in the KHCC Breast Imaging Unit) and to mark the biopsied axillary lymph node in the same session, and on that day consented participants were randomized to either axillary lymph node clip placement or tattooing after obtaining the intended axillary biopsy. Depending on the results of the biopsy, the KHCC breast MDC decided on the surgical management including the axillary treatment, the latter will be either sentinel lymph node biopsy (SLNBx)or axillary lymph node dissection (ALND). SLNBx will be performed on all recruited patients and to be followed by the standard axillary treatment as approved by KHCC clinical practice guidelines (either SLNBx alone or SLNBx followed by ALND). The group of patients with preoperative diagnosis of positive axillary nodes with undergo SLNBx as an extra procedure to test the study hypothesis and to be followed by ALND as per the KHCC protocol. The presence of the marking material will be confirmed prior to sending the SLNBx to the pathology department (by visualization of the tattoo and by X-ray examination of SLNBx looking for the clip). Patients whom receive ALND will have the presence of marking material checked in their specimens as well. This trial will study the concordance of both marking modalities with SLNBx identification ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05836337
Study type Interventional
Source King Hussein Cancer Center
Contact
Status Completed
Phase N/A
Start date February 1, 2017
Completion date August 20, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2